These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9314461)

  • 1. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis.
    Llanos-Cuentas A; Echevarría J; Cruz M; La Rosa A; Campos P; Campos M; Franke E; Berman J; Modabber F; Marr J
    Clin Infect Dis; 1997 Sep; 25(3):677-84. PubMed ID: 9314461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate.
    Martinez S; Gonzalez M; Vernaza ME
    Clin Infect Dis; 1997 Feb; 24(2):165-9. PubMed ID: 9114142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Effect Of Oral Allopurinol And Intralesional Sodium Stibogluconate In The Treatment Of Cutaneous Leishmaniasis.
    Rashid HU; Ullah I; Adeeb H; Zeb M; Mohammad A; Rehman N
    J Ayub Med Coll Abbottabad; 2020; 32(4):558-561. PubMed ID: 33225663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
    Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
    Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractional Ablative CO2 Laser Followed by Topical Application of Sodium Stibogluconate for Treatment of Active Cutaneous Leishmaniasis: A Randomized Controlled Trial.
    Artzi O; Sprecher E; Koren A; Mehrabi JN; Katz O; Hilerowich Y
    Acta Derm Venereol; 2019 Jan; 99(1):53-57. PubMed ID: 30281141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
    Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J
    Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chronic mutilating rhinopathy with a delayed diagnosis of mucocutaneous leishmaniasis.
    Karimbil SK; Kumari S; Celine MI; Joy A
    Int J Dermatol; 2010 Apr; 49(4):426-9. PubMed ID: 20465699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of ocular leishmaniasis.
    Abrishami M; Soheilian M; Farahi A; Dowlati Y
    Eur J Dermatol; 2002; 12(1):88-9. PubMed ID: 11809607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate.
    Halim MA; Alfurayh O; Kalin ME; Dammas S; al-Eisa A; Damanhouri G
    Clin Infect Dis; 1993 Mar; 16(3):397-9. PubMed ID: 8135901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractional ablative carbon dioxide laser followed by topical sodium stibogluconate application: A treatment option for pediatric cutaneous leishmaniasis.
    Hilerowicz Y; Koren A; Mashiah J; Katz O; Sprecher E; Artzi O
    Pediatr Dermatol; 2018 May; 35(3):366-369. PubMed ID: 29574997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Ramesh V; Kumar J; Kumar D; Salotra P
    Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
    Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD
    Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study.
    El-Sayed M; Anwar AE
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):335-40. PubMed ID: 19744259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy in Kala-azar.
    Singh NK; Jha TK; Singh IJ; Jha S
    J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
    PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis.
    Franke ED; Wignall FS; Cruz ME; Rosales E; Tovar AA; Lucas CM; Llanos-Cuentas A; Berman JD
    Ann Intern Med; 1990 Dec; 113(12):934-40. PubMed ID: 2173461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids as a novel approach to the treatment of disabling side effects of sodium stibogluconate.
    Brostoff JM; Lockwood DN
    J Clin Pharm Ther; 2012 Feb; 37(1):122-3. PubMed ID: 21457289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani.
    Ranawaka RR; Weerakoon HS
    J Dermatolog Treat; 2010 Sep; 21(5):286-93. PubMed ID: 20438389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.